Caracterización de pacientes con Hepatitis C en el servicio de hemodiálisis. Cienfuegos 2019 by Lizette Rodríguez Fernández, Evelyn Delgado Rodríguez, Aitana Blanco Morejón, Daniela de la Caridad Cedeño Díaz, Jayce Díaz Díaz, Jesús Julián Guada Delgado

Subjects: “…hepatitis c…”
Get full text

An Update on the Management of Chronic Hepatitis C: 2015 Consensus Guidelines from the Canadian Association for the Study of the Liver by Robert P Myers, Hemant Shah, Kelly W Burak, Curtis Cooper, Jordan J Feld

“…Chronic hepatitis C remains a significant medical and economic burden in Canada, affecting nearly 1% of the population. …”
Get full text

Formulation Design and Cell Cytotoxicity of Curcumin-Loaded Liposomal Solid Gels for Anti-Hepatitis C Virus by Helmy Yusuf, Erlyn K. D. D. Novitasari, Ni L. W. Purnami, Adhe W. Mahbub, Retno Sari, Dwi Setyawan

“…Anti-inflammatory and anti-hepatitis C virus (HCV) activities have been associated with CUR. …”
Get full text

Antineutrophil Cytoplasmic Antibody Induction due to Infection: A Patient with Infective Endocarditis and Chronic Hepatitis C by Fareed B. Kamar, T. Lee-Ann Hawkins

“…We also summarize previously reported cases of ANCA positivity in the context of endocarditis and hepatitis C infections.…”
Get full text

Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience) by I. Yu. Pirogova, N. B. Kovaleva, E. P. Patlusov, E. S. Radchenko

“…Overall 164 patients with hepatitis C viruses (HCV) genotypes 1, 2 and 3 in 4 medical centers received antiviral therapy. …”
Get full text

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C by L. Tang, M. Kamat, A. Shukla, M. Vora, C. Kalal, S. Kottilil, S. Shah

“…Background. Chronic hepatitis C infection is a major cause for liver failure and liver cancer and can be treated with highly effective all oral directly acting antiviral (DAA) drugs. …”
Get full text

Clinical role of endothelial dysfunction and hemostasis gene allelic variants in hepatitis C virus-associated cryoglobulinemia by M. V. Sokolova, Ye. Ye. Starostina, T. N. Krasnova, L. M. Samokhodskaya, T. P. Rozina, V. G. Avdeyev, M. G. Artemova, Ye. B. Yarovaya, N. A. Mukhin

“…To estimate the effect of carriage of endothelial dysfunction and hemostasis gene allelic variants on development of cryoglobulinemic vasculitis (CryoVas) and its clinical symptoms in patients with chronic hepatitis C (CHC). Material and methods. Original study included overall 72 patients with CHC and cryoglobulinemia: 21 patients had CryoVas, 51 - CHC without vasculitis. …”
Get full text

Early Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C by Louis WC Liu, George Tomlinson, Tony Mazzulli, Alison Murray, Jenny Heathcote

“…BACKGROUND: Treatment of chronic hepatitis C virus (HCV) infection with interferon alpha-2b and ribavirin is costly in terms of side effects, medical resources and drug costs. …”
Get full text

Lymphoma-Associated Monoclonal Cryoglobulinemic Glomerulonephritis and Relationship with Hepatitis C Virus Infection: A Case Report by Sangeeta Mutnuri, Hania Kassem, John Badalamenti, You-Wen Qian, Christopher Marquez, Marjan Afrouzian

“…We report a case of type I cryoglobulinemic glomerulonephritis in a patient with chronic hepatitis C who presented with acute renal failure. …”
Get full text

High Dose Consensus Interferon in Nonresponders to Interferon Alpha-2B and Ribavirin with Chronic Hepatitis C by David N Moskovitz, Pooma Manoharan, E Jenny Heathcote

“…OBJECTIVES: Approximately 60% of patients with chronic hepatitis C treated with a combination of interferon (IFN) alpha-2b and ribavirin are nonresponders. …”
Get full text

Multicentric Castleman's Disease in a Hepatitis C-Positive Intravenous Drug User: A Case Report by D. Y. Talukder, S. N. Delpachitra

“…We report a rare presentation of Castleman's disease in a hepatitis C-positive patient and present a short review of treatments described in other similar case reports and studies. …”
Get full text

Clinical Recommendations for the Use of Recombinant Human Erythropoietin in Patients with Hepatitis C Virus Being Treated with Ribavirin by Morris Sherman, Lawrence Cohen, Mary Anne Cooper, Magdy Elkashab, Victor Feinman, David Fletcher, Nigel Girgrah, Jenny Heathcote, Mark Levstik, William B McNaull, David Wong, Florence Wong, Colina Yim

“…Today, combination antiviral therapy with pegylated interferon-alpha and ribavirin (RBV) allows many patients infected with hepatitis C virus (HCV) to achieve a sustained virological response, which is equivalent to cure. …”
Get full text

Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary by Raymond Odhiambo, Jagpreet Chhatwal, Shannon Allen Ferrante, Antoine El Khoury, Elamin Elbasha

“…**Background:** Recent international, randomized, placebo-controlled clinical trials (SPRINT-2; RESPOND-2) demonstrated that the triple combination of peginterferon (PEG), ribavirin (RBV) and boceprevir (BOC) was more efficacious than the standard dual therapy of PEG and RBV in treatment of patients chronically infected with genotype 1 hepatitis C virus (HCV) infection. The objective of this study was to evaluate the cost-effectiveness of triple therapy in both treatment-naive and treatment-experienced patients in Hungary. …”
Get full text

Erythropoietin and Hepatitis C Therapy: Useful Adjuvant Therapy but Remember to Treat the Patient and Not Just a Number by Eric M Yoshida, Anne Dar Santos, Nilufar Partovi, Jo-Ann E Ford

Get full text

Epidemiology of chronic kidney disease and the heightened risk of hepatitis C virus infection in low-resource settings by Nuryati Anik, Budi Setiawan, Catur Wijayanti

Subjects: Get full text

Hepatitis C Worldwide and in Brazil: Silent Epidemic—Data on Disease including Incidence, Transmission, Prevention, and Treatment by Iara Fabricia Kretzer, Andrea do Livramento, Joel da Cunha, Sabrina Gonçalves, Iraci Tosin, Celso Spada, Aricio Treitinger

“…Hepatitis C virus (HCV) is endemic worldwide and according to the World Health Organization (WHO), there are about 150 million chronic carriers worldwide. …”
Get full text

Computational design of multi-epitope vaccine against Hepatitis C Virus infection using immunoinformatics techniques. by Sara Zubair, Fahed Parvaiz, Turki Abualait, Khalid Al-Regaiey, Tasneem Anwar, Mahnoor Zafar, Imdad Kaleem, Shahid Bashir

“…Hepatitis C Virus (HCV) is a blood borne pathogen that affects around 200 million individuals worldwide. …”
Get full text

Inflammasome Genes’ Polymorphisms in Egyptian Chronic Hepatitis C Patients: Influence on Vulnerability to Infection and Response to Treatment by Shady Z. K. Estfanous, Sahar A. Ali, Sameh M. Seif, Sameh H. A. Soror, Dalia H. A. Abdelaziz

“…Chronic inflammation is a pivotal contributor to the liver damage mediated by hepatitis C virus (HCV). The NOD-like receptor, pyrin domain-containing 3 (NLRP3) inflammasome is activated by HCV in both hepatocytes and Kupffer cells. …”
Get full text

Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis by Sarah R. Donaldson, Andrew Radley, John F. Dillon

Subjects: “…Hepatitis C…”
Get full text

Seroprevalence of hepatitis B and C virus among a group of hemophilia patients in Kurdistan Region, Iraq by Salih A. Hama

Subjects: Get full text